The potential of NHE1 as a target in the development of novel anti-cancer therapeutics was recently reviewed, highlighting key characteristics of NHE1 that could be exploited to combat the tumorigenic and metastatic capacity of cancer cells [42]. This evidence concerns the gene SLC9A1 and cancer.